Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for @entity816 and XXXX .

@entity1 @entity4174 @entity1862 @entity5 @entity33 @entity11770 @entity11 @entity816 @entity1891 @entity1485 @entity463 @entity1487
The survival rate for @entity1 with @entity11 is poor. We describe the results of a prospective study using concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for @entity1 with @entity11 . Forty-two @entity1 with @entity816 ( @entity816 ) and @entity463 ( @entity463 ) were treated with postoperative photon radiation 45 Gy/25 fraction (fxs) with concomitant continuous intravenous infusion of @entity1487 at 300 mg/m2/day x 5 days and @entity1862 0.5 g orally every 12 hr for 6 days for 5 consecutive weeks, followed by a neutron boost of 450 N cGy/6 fxs delivered twice weekly. Adjuvant chemotherapy with @entity4174 , @entity11770 , and @entity1891 ( @entity1485 ) was given up to 1 year or until @entity5 progression. Thirty-four @entity1 (81%) had @entity463 and 8 @entity1 (19%) had @entity816 . Sixteen @entity1 (38%) were ineligible for the neutron boost because of large @entity5 or poor performance status and instead received a photon boost with concomitant chemotherapy for a total dose of 60-65 Gy to the @entity5 . The overall median survival is 68 weeks at a median follow-up of 203 weeks (range 166-302 weeks for the 11 @entity1 remaining alive); 7/8 @entity1 with @entity816 are alive, 2 of these with progressive disease. For @entity816 the median survival is not reached at a median follow-up of 203 weeks (range 166-302 weeks for the 7 @entity1 alive with @entity816 ). Time to @entity5 progression for the 1 dead @entity1 with @entity816 was 35 weeks and the other 2 @entity1 failed at 171 weeks and 179 weeks following treatment. The median survival for the 34 @entity1 with @entity463 was 62 weeks; 4/34 @entity1 with @entity463 are alive at 285, 238, 216, and 206 weeks. Multivariate survival analysis in the 34 @entity1 with @entity463 revealed age and Karnofsky performance status as important prognostic factors. Extent of surgery and neutrons did not affect survival. Concomitant chemoradiotherapy was well tolerated by all @entity1 . The only toxicities observed were @entity33 < or = grade II in 3 @entity1 (7%) and mild myelosuppression in 1 @entity1 (2.4%). Adjuvant @entity1485 was well tolerated. Continuous concomitant chemoradiotherapy was well tolerated by all @entity1 with acceptable side effects. The survival rate for the @entity1 with @entity463 suggests no significant impact on the prognosis for these @entity1 . @entity1 with @entity816 did well; however, the @entity1 numbers are small.
